IMA-638 in Active Ulcerative Colitis: Efficacy and Safety from a Phase IIa Multicenter Study
Sunil Khurana, Walter Reinisch(Medical University of Vienna), Philip De Micco(Clinical Research Institute), Julián Panés(Hospital Clínic de Barcelona), Fabio Cataldi(Pfizer (United States)), Gail M. Comer(Pfizer (United States)), Tara McDonnell(Szent János Kórház), П. Т. Петров, Fei Hua(Soochow University), Karen Page(Pfizer (United States)), Gábor Tóth(Szent János Kórház), Beth Hanlon, Guojun Yuan(Pfizer (United States)), Michelle Hinz(Pfizer (United States))
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
|Nature Metabolism|2020|775